fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Imipramine was listed in the December 27, 2023 extract; the same DIN 00360201 is listed as Apo-Imipramine Tablets in the current extract (September 22, 2026). This is not an absent DIN. Source: odb-formulary-ed43-extract-2023-12-27.xml; odb-formulary-ed43-extract-2026-09-22.xml.

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Apo-imipramine tablets (imipramine) and other imipramine products

Imipramine

6 general benefit · 3 not a benefit

Apo-Imipramine Tablets · DIN 00360201 · 10 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Apo-Imipramine Tablets · DIN 00360201 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Marketed since 2026-01-20 · brand APO-IMIPRAMINE TABLETS · ATC N06AA02 IMIPRAMINE · form Tablet · route Oral · ingredients IMIPRAMINE HYDROCHLORIDE 10 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Imipramine Tablets: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1257). What the ministry pays, not the patient.

Ministry pays: $0.1257 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00360201)

Source record
DIN 00360201: Apo-Imipramine Tablets Raw flags: sec3=Y Item: 281604013; group id 463; item number 1161; lccId None; manufacturer id APX Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.1257; ministry $0.1257 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00360201 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2444
Interchangeable products
Jamp Imipramine · DIN 02546337 · $0.1257 Tofranil · DIN 00010464 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00360201
Shortage record checked October 6, 2026

Apo-Imipramine Tablets · DIN 00312797 · 25 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Apo-Imipramine Tablets · DIN 00312797 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Marketed since 2026-01-20 · brand APO-IMIPRAMINE TABLETS · ATC N06AA02 IMIPRAMINE · form Tablet · route Oral · ingredients IMIPRAMINE HYDROCHLORIDE 25 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Imipramine Tablets: Formulary list price $0.23 per unit (the source does not state the unit; exact figure $0.2316). What the ministry pays, not the patient.

Ministry pays: $0.2316 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00312797)

Source record
DIN 00312797: Apo-Imipramine Tablets Raw flags: sec3=Y Item: 281604012; group id 463; item number 1162; lccId None; manufacturer id APX Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.2316; ministry $0.2316 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00312797 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2211
Interchangeable products
Jamp Imipramine · DIN 02546345 · $0.2316 Tofranil · DIN 00010472 · not recorded
Shortage status: resolved shortage (ended March 10, 2021); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00312797
Shortage record checked October 6, 2026

Apo-Imipramine Tablets · DIN 00326852 · 50 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Apo-Imipramine Tablets · DIN 00326852 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Marketed since 2026-01-20 · brand APO-IMIPRAMINE TABLETS · ATC N06AA02 IMIPRAMINE · form Tablet · route Oral · ingredients IMIPRAMINE HYDROCHLORIDE 50 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Imipramine Tablets: Formulary list price $0.45 per unit (the source does not state the unit; exact figure $0.4519). What the ministry pays, not the patient.

Ministry pays: $0.4519 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00326852)

Source record
DIN 00326852: Apo-Imipramine Tablets Raw flags: sec3=Y Item: 281604011; group id 463; item number 1163; lccId None; manufacturer id APX Source form: Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $0.4519; ministry $0.4519 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00326852 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2212
Interchangeable products
Jamp Imipramine · DIN 02546353 · $0.4519 Tofranil · DIN 00010480 · not recorded
Shortage status: discontinued (May 27, 2016, reported by AA PHARMA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00326852
Shortage record checked October 6, 2026

Jamp Imipramine · DIN 02546337 · 10 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Jamp Imipramine · DIN 02546337 Manufacturer: Jamp Pharma Corporation; listing date 2025-04-30 Health Canada: Marketed since 2024-11-29 · brand JAMP IMIPRAMINE · ATC N06AA02 IMIPRAMINE · form Tablet · route Oral · ingredients IMIPRAMINE HYDROCHLORIDE 10 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp Imipramine: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1257). What the ministry pays, not the patient.

Ministry pays: $0.1257 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02546337)

Source record
DIN 02546337: Jamp Imipramine Raw flags: sec3=Y Item: 281604013; group id 463; item number 1161; lccId None; manufacturer id JPC Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.1257; ministry $0.1257 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02546337 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103504
Interchangeable products
Apo-Imipramine Tablets · DIN 00360201 · $0.1257 Tofranil · DIN 00010464 · not recorded
Shortage status: resolved shortage (ended January 15, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02546337
Shortage record checked October 6, 2026

Jamp Imipramine · DIN 02546345 · 25 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Jamp Imipramine · DIN 02546345 Manufacturer: Jamp Pharma Corporation; listing date 2025-04-30 Health Canada: Marketed since 2024-11-29 · brand JAMP IMIPRAMINE · ATC N06AA02 IMIPRAMINE · form Tablet · route Oral · ingredients IMIPRAMINE HYDROCHLORIDE 25 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp Imipramine: Formulary list price $0.23 per unit (the source does not state the unit; exact figure $0.2316). What the ministry pays, not the patient.

Ministry pays: $0.2316 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02546345)

Source record
DIN 02546345: Jamp Imipramine Raw flags: sec3=Y Item: 281604012; group id 463; item number 1162; lccId None; manufacturer id JPC Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.2316; ministry $0.2316 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02546345 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103505
Interchangeable products
Apo-Imipramine Tablets · DIN 00312797 · $0.2316 Tofranil · DIN 00010472 · not recorded
Shortage status: resolved shortage (ended September 23, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02546345
Shortage record checked October 6, 2026

Jamp Imipramine · DIN 02546353 · 50 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Jamp Imipramine · DIN 02546353 Manufacturer: Jamp Pharma Corporation; listing date 2025-04-30 Health Canada: Marketed since 2024-11-29 · brand JAMP IMIPRAMINE · ATC N06AA02 IMIPRAMINE · form Tablet · route Oral · ingredients IMIPRAMINE HYDROCHLORIDE 50 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp Imipramine: Formulary list price $0.45 per unit (the source does not state the unit; exact figure $0.4519). What the ministry pays, not the patient.

Ministry pays: $0.4519 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02546353)

Source record
DIN 02546353: Jamp Imipramine Raw flags: sec3=Y Item: 281604011; group id 463; item number 1163; lccId None; manufacturer id JPC Source form: Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $0.4519; ministry $0.4519 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02546353 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103506
Interchangeable products
Apo-Imipramine Tablets · DIN 00326852 · $0.4519 Tofranil · DIN 00010480 · not recorded
Shortage status: resolved shortage (ended September 23, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02546353
Shortage record checked October 6, 2026

Tofranil · DIN 00010464 · 10 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2001-07-30 — choose a marketed DIN from the same-category list.Discontinued July 30, 2001 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2001-07-30 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2001-07-30 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Tofranil · DIN 00010464 Manufacturer: Novartis Pharma Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2001-07-30 · brand TOFRANIL 10MG · ATC N06AA02 IMIPRAMINE · form Tablet · route Oral · ingredients IMIPRAMINE HYDROCHLORIDE 10 MG · company Novartis pharmaceuticals canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Tofranil: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00010464)

Source record
DIN 00010464: Tofranil Raw flags: notABenefit=Y, sec3=Y Item: 281604013; group id 463; item number 1161; lccId None; manufacturer id NOV Source form: Tab; strength: 10mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00010464 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=164
Interchangeable products
Apo-Imipramine Tablets · DIN 00360201 · $0.1257 Jamp Imipramine · DIN 02546337 · $0.1257
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00010464
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 30, 2001 — choose a marketed DIN from the same-category list.

Tofranil · DIN 00010472 · 25 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2008-07-18 — choose a marketed DIN from the same-category list.Discontinued July 18, 2008 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2008-07-18 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2008-07-18 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Tofranil · DIN 00010472 Manufacturer: Novartis Pharma Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2008-07-18 · brand TOFRANIL 25MG · ATC N06AA02 IMIPRAMINE · form Tablet · route Oral · ingredients IMIPRAMINE HYDROCHLORIDE 25 MG · company Novartis pharmaceuticals canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Tofranil: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00010472)

Source record
DIN 00010472: Tofranil Raw flags: notABenefit=Y, sec3=Y Item: 281604012; group id 463; item number 1162; lccId None; manufacturer id NOV Source form: Tab; strength: 25mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00010472 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2038
Interchangeable products
Apo-Imipramine Tablets · DIN 00312797 · $0.2316 Jamp Imipramine · DIN 02546345 · $0.2316
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00010472
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 18, 2008 — choose a marketed DIN from the same-category list.

Tofranil · DIN 00010480 · 50 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2010-11-29 — choose a marketed DIN from the same-category list.Discontinued November 29, 2010 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2010-11-29 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2010-11-29 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Tofranil · DIN 00010480 Manufacturer: Novartis Pharma Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2010-11-29 · brand TOFRANIL 50MG · ATC N06AA02 IMIPRAMINE · form Tablet · route Oral · ingredients IMIPRAMINE HYDROCHLORIDE 50 MG · company Novartis pharmaceuticals canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Tofranil: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00010480)

Source record
DIN 00010480: Tofranil Raw flags: notABenefit=Y, sec3=Y Item: 281604011; group id 463; item number 1163; lccId None; manufacturer id NOV Source form: Tab; strength: 50mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00010480 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1099
Interchangeable products
Apo-Imipramine Tablets · DIN 00326852 · $0.4519 Jamp Imipramine · DIN 02546353 · $0.4519
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00010480
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since November 29, 2010 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (N06AA): coverage varies; not interchangeable

  • Amitriptyline (Elavil): general benefit
  • Clomipramine (Anafranil Tab): general benefit
  • Desipramine (Pertofrane): general benefit, not a benefit
  • Doxepin (Sinequan): general benefit, not a benefit
  • Nortriptyline (Aventyl): general benefit
  • Trimipramine (Surmontil): general benefit, not a benefit

17 more in the class list below

Other drugs in the same formulary class (28:16:04 Antidepressants) and how they are covered

Matched class: 28:16:04 Antidepressants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMITRIPTYLINE, CLOMIPRAMINE HCL, FLUVOXAMINE MALEATE, NORTRIPTYLINE, PHENELZINE SULFATE, SERTRALINE HCL, TRANYLCYPROMINE SULFATE, VENLAFAXINE HCL, VORTIOXETINE HYDROBROMIDE Some products covered without a code (check the product listing): CITALOPRAM HYDROBROMIDE, DESIPRAMINE, DOXEPIN HCL, DULOXETINE, ESCITALOPRAM, FLUOXETINE HCL, MIRTAZAPINE, MOCLOBEMIDE, PAROXETINE HCL, TRAZODONE HYDROCHLORIDE, TRIMIPRAMINE 28:16:04 Antidepressants

AMITRIPTYLINE

· 12 products · General benefit · strengths: 10mg, 25mg, 50mg · Tab

CLOMIPRAMINE HCL

· 5 products · General benefit · strengths: 25mg, 50mg, 10mg · Tab

DESIPRAMINE

· 7 products · Listed, not a benefit (4), General benefit (3) · strengths: 25mg, 50mg, 75mg · Tab

DOXEPIN HCL

· 20 products · General benefit (12), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 10mg, 25mg, 50mg, 75mg, 100mg · Cap

NORTRIPTYLINE

· 2 products · General benefit · strengths: 10mg, 25mg · Cap

TRIMIPRAMINE

· 10 products · Listed, not a benefit (5), General benefit (5) · strengths: 75mg, 12.5mg, 25mg, 50mg, 100mg · Cap, Tab

CITALOPRAM HYDROBROMIDE

· 51 products · Off-Formulary Interchangeable, not an ODB benefit (9), General benefit (42) · strengths: 10mg, 20mg, 40mg · Tab

DULOXETINE

· 40 products · Listed, not a benefit (2), General benefit (38) · strengths: 30mg, 60mg · DR Cap

ESCITALOPRAM

· 40 products · Listed, not a benefit (2), General benefit (38) · strengths: 10mg, 20mg · Orally Disintegrating Tab, Orally Disintegrating Tablet, Tab

FLUOXETINE HCL

· 41 products · Off-Formulary Interchangeable, not an ODB benefit (17), Listed, not a benefit (2), General benefit (22) · strengths: 10mg, 20mg, 40mg, 60mg, 20mg/5mL · Cap, Oral Sol

FLUVOXAMINE MALEATE

· 6 products · General benefit · strengths: 50mg, 100mg · Tab

MIRTAZAPINE

· 25 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 15mg, 30mg, 45mg · Orally Disintegrating Tab, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 28:16:04 and 12 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS APO-IMIPRAMINE TABLETS (imipramine hydrochloride tablets) is indicated for: • The relief of symptoms of depressive illness. As with other tricyclic antidepressants, APO-IMIPRAMINE TABLETS may precipitate hypomanic episodes in patients with bipolar depression. These drugs are not indicated in mild depressive states and depressive reactions. 1.1 Pediatrics Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (≥65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. See 4.2 Recommended Dose and Dosage Adjustment and 7.1.4 Geriatrics. https://pdf.hres.ca/dpd_pm/00081234.PDF PM date: JUL 25, 2025 Source product: APO-IMIPRAMINE TABLETS; DIN 00312797; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Apo-Imipramine Tablets · DIN 00326852 Shortage status: discontinued (2016-05-27, reported by AA PHARMA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00326852

Check this DIN again

Other review policies

For Tofranil: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026